Concepedia

Danny Sugimoto

DS

15

Publications

1.5K

Citations

13

H-Index

1996

Active since

Affiliations

Novo Nordisk (Denmark)(Current)

University of Pennsylvania

University of Alabama at Birmingham

Boehringer Ingelheim (Germany)

Novo Nordisk (United States)

Danny Sugimoto is an author at Novo Nordisk (Denmark) specializing in pharmacotherapy, medicine, and pharmacology.

ORCID

Top concepts

Publications per year

1996–2023

15

Publications

15

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

Helena W. Rodbard, Ildiko Lingvay, John H. Reed et al. · The Journal of Clinical Endocrinology & Metabolism · 2018 · 353 citations · Full text

Triple Therapy in Type 2 Diabetes

Julio Rosenstock, Danny Sugimoto, Poul Strange et al. · Diabetes Care · 2006 · 236 citations · Full text

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial

Thomas A. Wadden, Jena Shaw Tronieri, Danny Sugimoto et al. · Obesity · 2020 · 183 citations · Full text

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

W. Timothy Garvey, Andreas L. Birkenfeld, Dror Dicker et al. · Diabetes Care · 2020 · 170 citations · Full text

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

Katherine R. Tuttle, Sibylle J. Hauske, María Eugênia Fernandes Canziani et al. · The Lancet · 2023 · 151 citations · Full text

, , +10

Rows per page

1–5 of 15